Nitin Jain, MD, is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center in Houston. He earned his medical degree from the All India Institute of Medical Sciences, New Delhi. He completed Internal Medicine residency at the Medical College of Wisconsin and fellowship in Hematology/Oncology at the University of Chicago. Dr. Jain research interests include new drug development for patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). Dr. Jain is Principal Investigator of several investigator-initiated phase I-II clinical trials, including combination targeted therapies (ibrutinib and venetoclax) in CLL, checkpoint inhibitors in Richter transformation, novel CD22 antibody drug conjugate in B-ALL, venetoclax + chemotherapy in B- and T-ALL, and off-the-self allogeneic CAR-T in B-ALL. The trial combining ibrutinib and venetoclax was published in New England Journal of Medicine in 2019. He has won many awards including ASCO merit award, Sabin Family Foundation Award in 2018 and MD Anderson Faculty Scholar award in 2020.